Key Takeaways
- Side effects reported to date are mild — chiefly gastrointestinal discomfort, fatigue and occasional headache — but frequency data does not exist because large-scale human trials have not been run.
- No serious adverse events are documented in the available literature, which reflects the small evidence base as much as it reflects safety.
- Typical clinical dosing is 5–25 mg per subcutaneous injection, 2–5 times per week, with most protocols starting at 5–10 mg to assess tolerance.
- MOTS-c is not FDA-approved and is not a controlled substance. Availability through US compounding pharmacies is limited and varies by pharmacy.
- Long-term safety data is lacking. Discuss potential risks with a healthcare provider before use.
What Is MOTS-c?
MOTS-c is a mitochondrial-derived peptide composed of 16 amino acids, encoded by the mitochondrial genome. It plays a role in cellular metabolism and is currently being researched for its potential therapeutic benefits in metabolic disorders like diabetes and age-related diseases. For more detailed information, visit the full MOTS-c profile.
Because it was first described in human cells only in 2015, its regulatory history is short and its research base is correspondingly thin compared with older peptides.
How MOTS-c Works in the Body
MOTS-c is encoded by the mitochondrial genome, specifically the 12S rRNA region, and consists of 16 amino acids. MOTS-c translocates to the nucleus under metabolic stress, regulating nuclear gene expression to maintain cellular homeostasis (PMID 36761202).
The peptide's mechanism of action involves enhancing glucose metabolism, particularly in skeletal muscle, which is of interest for conditions such as diabetes and metabolic syndrome (PMID 34798268). MOTS-c's receptor binding affinity, half-life, and bioavailability are critical factors that influence its dosing. Its short half-life necessitates frequent administration to maintain therapeutic levels, while its bioavailability is maximized through subcutaneous injection.
"MOTS-c has been shown to improve glucose metabolism in skeletal muscle, indicating potential benefits for diseases such as diabetes, obesity, and age-related conditions." — PMID 36761202
Standard MOTS-c Dosage Ranges
MOTS-c is dosed at 5–25 mg in most off-label clinical protocols, administered via subcutaneous injection on a cyclical schedule.
| Parameter | Typical Clinical Protocol |
|---|---|
| Dose | 5–25 mg per injection |
| Frequency | 2–5 times per week |
| Route | Subcutaneous injection |
| Cycle | 4–12 weeks on; 4 weeks off |
| Common stack | Often combined with NAD+, Epithalon, or GLP-1 peptides |
Most clinics initiating MOTS-c start at the lower end (5–10 mg) to assess tolerance before escalating. The 10 mg dose 3x/week is a common maintenance protocol. Subcutaneous administration is the standard; alternate forms such as oral or topical are uncommon because of lower bioavailability, as subcutaneous injection allows the peptide to reach systemic circulation without digestive degradation.
MOTS-c Dosage by Use Case
Metabolic enhancement. Around 10 mg per subcutaneous injection over a 4–6 week cycle. Research indicates MOTS-c influences glucose metabolism (PMID 34798268 — a study in gestational diabetes mellitus). Many clinics recommend this dosing for patients seeking metabolic improvements.
Anti-aging. Around 5–10 mg per subcutaneous injection over a 6–8 week cycle. MOTS-c levels decline with age, which is the rationale for supplementation (PMID 36233287). Clinics often tailor doses based on patient age and baseline MOTS-c levels.
Oncology research. MOTS-c has been shown to suppress ovarian cancer progression in laboratory models (PMID 39321430). This is mechanistic preclinical work, not a human treatment protocol, and no dose in this article should be read as a cancer therapy. MOTS-c is not a cancer treatment.
How Long Should You Take MOTS-c?
Typical MOTS-c cycles range from 4 to 12 weeks depending on the therapeutic goal, commonly followed by around 4 weeks off. During the first week, patients might experience mild side effects as the body adjusts. From weeks 2–4, metabolic improvements are often reported. By week 6, sustained benefits are typically observed, and tapering is not usually necessary unless advised by a healthcare provider. Discontinuation should be monitored for any return of symptoms or metabolic issues.
A typical clinic visit structure looks like baseline metabolic labs (glucose, insulin, HbA1c, CRP, IGF-1), a starting protocol of 5–10 mg subcutaneously 2–3x per week, a 4-week reassessment with follow-up labs, and dose escalation if well tolerated.
Administration Protocol: How to Take MOTS-c
| Parameter | Specification |
|---|---|
| Needle gauge | 29–31 gauge insulin syringe |
| Injection sites | Abdomen, thigh, or upper arm |
| Rotation schedule | Rotate sites with each injection to minimize irritation |
| Storage temperature | 2–8°C (36–46°F) |
| Light sensitivity | Protect from light |
| Reconstituted stability | Use within 28–30 days when stored correctly |
Step by step. Wash hands and clean the injection site with alcohol. Reconstitute following our reconstitution guide. Pinch the skin, insert the needle at a 45-degree angle, and inject slowly. Dispose of the needle safely and apply gentle pressure to the site.
MOTS-c Reconstitution
MOTS-c is supplied as a lyophilized powder. Reconstitute with bacteriostatic water:
- 5 mg vial + 1 mL BAC water = 5 mg/mL; 1 mL draws a full 5 mg dose
- 10 mg vial + 2 mL BAC water = 5 mg/mL; allows precise dosing with insulin syringe
- Store reconstituted vial at 2–8°C; use within 28–30 days
Use our peptide calculator to determine exact syringe units for your dose and concentration.
Stacking MOTS-c
MOTS-c and BPC-157. Used for enhanced tissue repair and metabolic benefits, dosing MOTS-c (10 mg) with BPC-157 (250 mcg). Often used in recovery and anti-aging protocols.
MOTS-c and Epitalon. Aimed at anti-aging and longevity, dosing MOTS-c (5 mg) with Epitalon (10 mg). Utilized in age-related research for synergistic effects.
Factors That Affect Your MOTS-c Dosage
Individual factors such as body weight, age, and specific treatment goals significantly influence MOTS-c dosing. Providers may adjust doses for individuals with compromised kidney or liver function or those on concurrent medications. Personalized dosing ensures optimal efficacy and safety, as a one-size-fits-all approach is inadequate.
Common Dosing Mistakes to Avoid
- Dosing Too High/Too Low: Incorrect dosing can lead to suboptimal results or increased side effects.
- Inconsistent Timing: Regular administration is crucial for maintaining therapeutic levels.
- Wrong Injection Site: Use recommended sites to ensure proper absorption.
- Not Accounting for Regulatory Status: Understand that MOTS-c is for research use and not FDA-approved.
- Poor Storage/Handling: Improper storage can degrade the peptide, reducing efficacy.
Common MOTS-c Side Effects
While MOTS-c is still under investigation and not approved for clinical use, some studies and anecdotal reports have highlighted potential side effects:
- Gastrointestinal Discomfort: Some users report mild nausea or diarrhea. However, precise frequency data is unavailable due to the lack of large-scale human trials.
- Fatigue: Temporary fatigue has been noted in anecdotal reports, though this is not systematically studied.
- Headache: Occasional headaches have been mentioned in user reports, but these are not consistently documented in clinical settings.
These side effects are primarily derived from preclinical studies or limited human observations (PMID 36761202).
Serious or Rare Side Effects
To date, there are no well-documented serious adverse events associated with MOTS-c in the available literature. However, given its research-only status, comprehensive post-marketing surveillance data is lacking. As with any peptide therapy, the potential for unforeseen side effects exists, particularly with long-term use.
Side Effects by Administration Route
MOTS-c is predominantly administered via injection. The route of administration can influence the side effect profile:
- Injectable: Local site reactions such as redness or swelling might occur, although specific data for MOTS-c is sparse.
